Epsilon Protein kinase C (epsilon PCK) is a particular kinase that, when activated, is able to protect against different stress injuries and therefore has been proposed to be a potential molecular target against acute and chronic diseases. Particular attention has been focused on epsilon PCK for its involvement in the protective mechanism of lschemic Preconditioning (IPC), a powerful endogenous mechanism characterized by subthreshold ischemic insults able to protect organs against ischemic injury. Therefore, in the past decades several epsilon PCK modulators have been tested with the object to emulate epsilon PCK mediate protection. Among these the most promising, so far, has been the Psi epsilon RACK peptide, a homologous of RACK receptor for epsilon PKC, that when administrated can mimic its effect in the cells. However, results from studies on epsilon PCK indicate controversial role of this kinase in different organs and diseases, such as myocardial infarct, stroke, diabetes and cancer. Therefore, in this review we provide a discussion on the function of epsilon PCK in acute and chronic diseases and how the different activators and inhibitors have been used to modulate its activity. A better understanding of its function is still needed to definitively target epsilon PCK as novel therapeutic strategy. (C) 2016 Elsevier Ltd. All rights reserved.
The role of epsilon PKC in acute and chronic diseases: Possible pharmacological implications of its modulators
Pastore D;Guadagni F;
2016-01-01
Abstract
Epsilon Protein kinase C (epsilon PCK) is a particular kinase that, when activated, is able to protect against different stress injuries and therefore has been proposed to be a potential molecular target against acute and chronic diseases. Particular attention has been focused on epsilon PCK for its involvement in the protective mechanism of lschemic Preconditioning (IPC), a powerful endogenous mechanism characterized by subthreshold ischemic insults able to protect organs against ischemic injury. Therefore, in the past decades several epsilon PCK modulators have been tested with the object to emulate epsilon PCK mediate protection. Among these the most promising, so far, has been the Psi epsilon RACK peptide, a homologous of RACK receptor for epsilon PKC, that when administrated can mimic its effect in the cells. However, results from studies on epsilon PCK indicate controversial role of this kinase in different organs and diseases, such as myocardial infarct, stroke, diabetes and cancer. Therefore, in this review we provide a discussion on the function of epsilon PCK in acute and chronic diseases and how the different activators and inhibitors have been used to modulate its activity. A better understanding of its function is still needed to definitively target epsilon PCK as novel therapeutic strategy. (C) 2016 Elsevier Ltd. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
